New hope for lymphoma patients: experimental combo aims to shrink tumors
NCT ID NCT05551936
Summary
This study is testing whether adding a new drug called tazemetostat to a standard two-drug regimen (bendamustine and rituximab) is safe and effective for adults with high-tumor-burden follicular lymphoma who have not had prior treatment. The main goals are to see if the three-drug combination is safe (Phase 1) and if it leads to a complete metabolic response—meaning no detectable cancer on a PET scan—after a short, six-cycle treatment course (Phase 2).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.